Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Profit After Tax (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Profit After Tax for 7 consecutive years, with -$6.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Profit After Tax rose 28.66% to -$6.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$38.2 million, a 21.66% increase, with the full-year FY2024 number at -$38.2 million, up 21.66% from a year prior.
  • Profit After Tax was -$6.7 million for Q4 2024 at Actinium Pharmaceuticals, up from -$11.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$5.0 million in Q2 2021 to a low of -$15.2 million in Q2 2023.
  • A 4-year average of -$9.1 million and a median of -$9.0 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: tumbled 115.19% in 2023, then rose 28.66% in 2024.
  • Actinium Pharmaceuticals' Profit After Tax stood at -$8.0 million in 2021, then crashed by 32.92% to -$10.6 million in 2022, then increased by 12.43% to -$9.3 million in 2023, then grew by 28.66% to -$6.7 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Profit After Tax are -$6.7 million (Q4 2024), -$11.6 million (Q3 2024), and -$11.4 million (Q2 2024).